If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
63
results.
Updated on
12/11/2025 [07:26:00]
Absstract of: MX2024001835A
Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD 163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.
Absstract of: AU2024274218A1
The present invention refers to the use of a biomarker for measuring the efficacy or effectiveness of treatments for neurodegenerative diseases, in particular, for Alzheimer's disease.
Absstract of: US2025341530A1
The present disclosure relates to immunoassays for NF-L performed on liquid samples derived from physiological fluids such as venous blood to detect the presence or absence of a physiological condition by quantifying one or a combination of NF-L determinations at concentrations indicative of the condition.
Absstract of: US2025340941A1
Disclosed herein are methods for assaying a potential drug candidate for the treatment, prevention, reduction or amelioration of neurodegenerative diseases and disorders. Some aspects pertain to stimulating a cell to induce a phenotype characteristic of a neurodegenerative disease or disorder and contacting the cell with a potential drug candidate and determining a responsive change, wherein a decrease or loss in the phenotype is indicative that the drug candidate is capable of treating, preventing, reducing or ameliorating neurodegenerative diseases or disorders.
Absstract of: US2025339434A1
A process for treating a human subject with a neurologic disorder comprises obtaining a sample of the human subject. The sample is contacted with an assay for detecting a presence of soluble folate binding protein (sFBP), one or more single nucleotide polymorphism (SNP) in folate or related one-carbon metabolism genes, or both. Based on the whether there is a presence of sFBP, a presence of SNPs, an amount of folate receptor alpha autoantibody (FRAA) (i.e., FRAA titer), or a combination thereof in the sample, a treatment including a folate is created. The treatment is then administered to the human subject.
Absstract of: WO2025231348A1
Provided are methods of phospho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, treatment, and identification of the presence of pretangles in a subject. Novel p-tau sites, p-tau198, p-tauS356, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Absstract of: EP4644569A2
The present disclosure provides methods and systems for mapping gene and protein expression in a cell (i.e., mapping gene and protein expression within the same cell simultaneously). The present disclosure also provides methods for diagnosing a disease or disorder (e.g., a neurological disorder such as Alzheimer's disease) in a subject. Methods of screening for a candidate agent capable of modulating gene and/or protein expression are also provided by the present disclosure. The present disclosure also provides methods for treating a disease or disorder, such as Alzheimer's disease, in a subject in need thereof. A plurality of oligonucleotide probes, which may be useful for performing the methods described herein, are also described by the present disclosure, as well as kits comprising any of the oligonucleotide probes described herein. Additionally, the present disclosure provides methods, apparatuses, and non-transitory computer-readable storage media for identifying spatial variations of cell types in at least one image.
Absstract of: MX2025011654A
The present invention relates to anti-a-synuclein antibodies, which preferentially recognize a-synuclein aggregates, and uses for detection, diagnosis, and/or treatment or prevention of a variety of diseases or disease symptoms related thereto due to accumulation of a-synuclein aggregates by using the anti-a-synuclein antibodies.
Absstract of: MX2025011444A
The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes for use in treating or preventing diseases associated with extracellular trap release from cells, such as Neutrophil Extracellular Trap (NET)- associated pathologies (NET associated pathology) or Eosinophil Extracellular Trap (EET) -associated pathologies (EET-associated pathology), wherein the methods comprising administering at least one dose of the antibody at a specific concentration. The invention also provides the methods themselves. The NET-associated pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, Anti-phospholipid Syndrome, Bechet's disease, spondylitis, spondyloarthropathy, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, nongranulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or other NET-associated pathologies such as wound healing in diabetes, cancer, cancer metastasis, and transplant organ health in vivo or ex vivo. The invention a
Absstract of: JP2025029000A
To provide a method for detecting a neurodegenerative disease of a subject, and a method for treating the subject.SOLUTION: A method includes a step of detecting a level of exosome-associated coagulation biomarkers in a specimen collected from a subject. In the method, an increased level of exosome-associated coagulation biomarkers compared to a reference level indicates that the subject is suffering from a neurodegenerative disease.SELECTED DRAWING: None
Absstract of: US2025334583A1
Provided is a method for analyzing a neurogranin-related peptide capable of suppressing variations in analysis results, and a method for preparing a biological sample containing a neurogranin-related peptide used therein. The method includes mixing a biological sample containing a neurogranin-related peptide with an organic solvent having a relative polarity of 0.200 or more and 0.700 or less to prepare a sample solution having a final concentration of the organic solvent of 5.0 (v/v) % or more.
Absstract of: US2025334585A1
Antigen-binding molecules (ABMs) that bind to Porphyromonas gingivalis are described. The ABMs may be human or humanized ABMs. The ABMs find use in treating infections involving P. gingivalis, such as periodontal disease. Also provided are methods of treating or preventing a disorder or disease by administering the ABM.
Absstract of: US2025334594A1
Provided herein are methods and kits for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia. Also provided are methods of predicting or measuring a response to a treatment by measuring biomarker levels in a sample, and methods of modulating biomarker levels.
Absstract of: AU2024284125A1
Disclosed herein are methods for detecting the presence of at least one misfolded form of human Superoxide Dismutase 1 (SOD1) in a biological sample obtained from a human subject. In some aspects, the subject is suspected of having, or has, one or more neurodegenerative diseases, such as, for example, Amyotrophic Lateral Sclerosis, Parkinson's disease, or Alzheimer's disease.
Absstract of: AU2024235526A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Absstract of: US2024159777A1
This invention provides methods for determining whether a subject has a condition correlative with a matrix effect comprising (a) admixing (i) a suitably diluted sample of a suitable fluid from the subject and (ii) a suitable amount of a labeled molecule, wherein the labeled molecule is subject to a matrix effect with respect to the suitable fluid in a subject afflicted with the condition, and (b) after a suitable duration under suitable conditions, determining the amount of matrix-unaffected labeled molecule present in the resulting admixture, wherein the subject is afflicted with the condition if the amount of matrix-unaffected labeled molecule determined in step (b) correlates with a positive control for the condition, and wherein the subject is not afflicted with the condition if that amount correlates with a negative control for the condition. This invention also provides related methods, kits, and compositions. The present methods and kits are particularly useful for predicting the onset of neurodegenerative disorders such Alzheimer's disease and Parkinson's disease.
Absstract of: CN120129834A
A protein marker Nell-1 is provided that is present in a blood sample of a human in an amount associated with neurodegenerative diseases such as Alzheimer's disease (AD), mild cognitive impairment (MCI), and Parkinson's disease (PD). Also provided are corresponding diagnostic and therapeutic methods for these neurodegenerative diseases, as well as kits for diagnosing or treating neurodegenerative diseases.
Absstract of: US2025329454A1
A method to evaluate individuals with certain neurodegenerative diseases (e.g., Parkinson's Disease) in relation to etiologic diagnosis, prognosis and response to therapy involving the noninvasive collection of a biologic sample (e.g., venous blood), isolation of small, neuronally-derived, extracellular vesicles (e.g., exosomes), assay of their external and/or internal contents for quantities of informative biomarkers (e.g., signaling kinases, catalytic proteins and miRNA species) for the construction of a diagnostic/prognostic/response algorithms of clinical utility.
Absstract of: US2025327081A1
The invention relates to a short single-stranded DNA or RNA aptamer that is capable of binding the TDP-43 protein and of detecting all of the different TDP-43 structures individually, from the soluble monomer to the TDP-43 larger aggregates. The aptamer of the invention is also capable of inhibiting aggregation of TDP-43. Because of these properties, the RNA aptamer of the invention is suitable for use in both the diagnosis and therapeutic treatment and prevention of TDP-43-related proteinopathies, such as ALS and FTD.
Absstract of: US2025325682A1
The invention is directed to peptide fragments of FKBP52 that inhibit Tau protein aggregation and ameliorate tauopathies like Alzheimer's Disease (AD). It also involves modifications to these peptides to improve their pharmacokinetic and pharmacodynamic properties.
Absstract of: US2025325551A1
A method of diagnosing Alzheimer's disease and related dementias (ADRD) in a patient comprising obtaining a plasma sample from the patient; determining a level of a biochemical sulfide in the plasma sample from the subject by trapping volatilized H2S in the plasma sample using alkaline buffer with monobromobiamine, and detecting the level of biochemical sulfide in the plasma sample, the biochemical sulfide being one of acid-labile sulfide, bound sulfide, and total sulfide; and diagnosing the patient with ADRD when the level of the biochemical sulfide is at least an elevated threshold level for the biochemical sulfide.
Absstract of: AU2024249796A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Absstract of: MX2025003197A
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Absstract of: US2025320293A1
Provided is an anti-TREM2 single-domain antibody, consisting of heavy chains including CDR1 represented by any one of SEQ ID NOs: 34-40, CDR2 represented by any one of SEQ ID NOs: 41-45, and CDR3 represented by any one of SEQ ID NOs: 46-50. The single-domain antibody has good affinity with TREM2.
Nº publicación: US2025320495A1 16/10/2025
Applicant:
HOUSEY PHARMACEUTICAL RES LABORATORIES L L C [US]
Housey Pharmaceutical Research Laboratories, L.L.C
Absstract of: US2025320495A1
Provided herein are methods for modulating follistatin, such as inhibiting follistatin, suppressing the production of follistatin, reducing the level of follistatin, inhibiting the function of follistatin, or a combination thereof. The method can include administration of a compound that acts to modulate follistatin. In one embodiment, the compound is administered to a patient having or at risk or having a disease or condition selected from diabetes, pre-diabetes, metabolic syndrome, insulin resistance, dementia, and obesity, and optionally the disease or condition is prevented, treated, ameliorated, or a combination thereof.
BOPI
Electronic site
